Effects of monoamine oxidase inhibitors on isoproterenol-induced cardiomegaly in rats.
D000818:Animals; D002247:Carbon Isotopes; D006332:Cardiomegaly / Q000139:chemically induced / Q000188:drug therapy*; D004247:DNA / Q000032:analysis; D005260:Female; D005998:Glycine / Q000378:metabolism; D007520:Isocarboxazid / Q000627:therapeutic use; D007538:Isoniazid / Q000627:therapeutic use; D007545:Isoproterenol; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009206:Myocardium / Q000201:enzymology; D009526:Nialamide / Q000627:therapeutic use; D009696:Nucleic Acids / Q000378:metabolism; D010293:Pargyline / Q000627:therapeutic use; D010624:Phenelzine / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D012313:RNA / Q000032:analysis; D051381:Rats; D014191:Tranylcypromine / Q000627:therapeutic use
D002247:Carbon Isotopes; D008996:Monoamine Oxidase Inhibitors; D009696:Nucleic Acids; D010880:Piperidines; D011719:Pyrazines; D007520:Isocarboxazid; D014191:Tranylcypromine; D012313:RNA; D004247:DNA; D010293:Pargyline; D007545:Isoproterenol; D010624:Phenelzine; D009526:Nialamide; D005998:Glycine; D007538:Isoniazid